No long-term safety trial exists for injectable use
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
Effectiveness loss Subjective but important indicator: Peptide stopped working as well Need higher doses for same effect Complete loss of expected benefits Example: BPC-157 was reducing pain, but suddenly stops helping
Cognitive Function Beyond memory-specific tasks, Dihexa has attracted broader interest for its potential effects on focus, problem-solving, and overall mental performance
Why does it matter where the peptides come from
Some women experience brief nausea, especially during the first few doses